CARDIAC AUTONOMIC CONTROL MARKET ANALYSIS

Cardiac Autonomic Control Market, By Product Type (Heart Rate Variability (HRV) Monitors, Blood Pressure Monitors, ECG Monitors, and Others), By Application (Diagnostics, Therapeutics, and Research), By End User (Hospitals and Clinics, Home Users, Research Institutes, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Global Cardiac Autonomic Control Market- Recent Developments

Partnerships & Agreements

In January 2021, Boston Scientific, a global medical technology company, announced that it had entered into a definitive agreement to acquire Preventice Solutions, Inc., a company that offers a full portfolio of mobile cardiac health solutions and services, including ambulatory cardiac monitors, short and long-term Holter monitors, cardiac event monitors and mobile cardiac telemetry among others.

Key Strategic Initiatives

In August 2021, Fitbit, a consumer electronics company, launched Fitbit Luxe and Fitbit Luxe Special Edition smart tracker. The smart tracker can monitor breathing rate, heart rate variability (HRV), resting heart rate (RHR) and skin temperature variation.
In February 2022, InBody, a healthcare company, announced the launch of BP 170 automatic blood pressure monitor. The newly launched device provides individuals with the option to self-record and track key health metrics at home.
In July 2023, Abbott, a global medical device company, announced the U.S. Food and Drug Administration (FDA) approval for AVEIRdual chamber (DR) leadless pacemaker system. It is the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms.
In May 2023, Medtronic, a global medical device company, received U.S. FDA approval for Micra AV2 and Micra VR2, the next generation of its miniaturized, leadless pacemakers